<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Undifferentiated inflammatory arthritis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Undifferentiated inflammatory arthritis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Undifferentiated inflammatory arthritis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Josef S Smolen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Simon M Helfgott, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13880692"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The terms "undifferentiated arthritis" and "undifferentiated inflammatory arthritis" (UA) are used to describe patients with inflammatory arthritis that has not differentiated into a specific rheumatic disease, such as rheumatoid arthritis (RA) or psoriatic arthritis (PsA).</p><p>UA is most frequently used to describe patients during the first weeks to months following symptom onset, when it may not be possible to establish a specific diagnosis. However, UA also describes patients who fail to differentiate into another rheumatic disease, even after prolonged follow-up.</p><p>Patients with UA must often start therapy before it is clear whether their disease will evolve into another diagnosis, resolve spontaneously, or remain undifferentiated. Early treatment must be initiated to alleviate symptoms and to prevent the development of functional impairment caused by an untreated inflammatory arthritis [<a href="#rid1">1-9</a>].</p><p>The evaluation and management of patients with UA will be presented in this topic. The evaluation of patients with monoarticular and polyarticular pain and specific rheumatic diseases associated with an inflammatory arthritis are described in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1820.html" rel="external">"Monoarthritis in adults: Etiology and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7795.html" rel="external">"Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis"</a>.)</p><p></p><p class="headingAnchor" id="H366390463"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – An undifferentiated arthritis (UA) is present in approximately a quarter to a third of patients presenting with an early arthritis (ie, less than two to three months of symptoms) [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – The incidence of UA ranges from 41 to 149 per 100,000 adults [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H366390477"><span class="h1">CLINICAL AND LABORATORY FEATURES</span><span class="headingEndMark"> — </span>Undifferentiated arthritis (UA) is not a single disorder. UA encompasses patients who do not meet criteria for another inflammatory arthritis. Therefore, there are no clinical, laboratory, or radiographic features that are found in all patients with UA.</p><p>The clinical and laboratory features associated with UA were described in a cohort of 776 patients prospectively evaluated in an early arthritis clinic in the Netherlands [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morning stiffness</strong> – Morning stiffness lasted for less than an hour in 46 percent of patients (median of 30 minutes, interquartile range [IQR] 0 to 60 minutes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Swollen joint count</strong> – Most patients (65 percent) had fewer than four swollen joints. Only 6 percent of patients had more than 10 swollen joints.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Joint distribution</strong> – Arthritis affected the upper extremities (especially the hands) in 76 percent of patients, and 48 percent had symmetric joint involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute phase reactants</strong> – Half of patients had normal acute phase reactants (ie, C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]). The median ESR was 16 mm/h (IQR 8 to 36 mm/h) and the median CRP was 8 mg/L (IQR 3 to 23 mg/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoantibodies</strong> – Rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) were each present in 10 percent of patients.</p><p></p><p>A second study of 310 patients with UA from the Netherlands examined the one-year outcomes among patients with UA who lacked autoantibodies. This study determined that patients with UA fell into one of five clinical presentations [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polyarthritis</strong> (ie, more than four swollen joints) – 20 percent of cohort patients</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oligoarthritis</strong> (ie, two to four swollen joints) – 43 percent of cohort patients</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wrist monoarthritis</strong> – 9 percent of cohort patients</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large-joint monoarthritis</strong> (eg, hip, shoulder, knee) – 18 percent of cohort patients</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small-joint monoarthritis</strong> (eg, hands, feet) – 29 percent of cohort patients</p><p></p><p>However, the meaning of UA has continued to evolve with time. With this evolution, the clinical features associated with this diagnosis have also changed; in particular, patients with UA now have milder disease than had been reported previously.</p><p>Many patients who previously would have been diagnosed as having UA are now diagnosed as having rheumatoid arthritis (RA) [<a href="#rid11">11</a>]. This has been particularly true following the publication of the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for RA, which were developed to capture patients with early forms of RA [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3324038"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Undifferentiated arthritis (UA) is a diagnosis of exclusion. Therefore, the bulk of the diagnostic evaluation focuses on excluding other causes of inflammatory arthritis.</p><p class="headingAnchor" id="H1684483488"><span class="h2">Identification of inflammatory arthritis</span><span class="headingEndMark"> — </span>The first step towards diagnosing UA is to establish the presence of an inflammatory arthritis consistent with UA. This requires the detection of clinical joint swelling.</p><p>Clinical joint swelling can generally be identified with a musculoskeletal examination alone. However, imaging can be helpful to confirm equivocal examination findings.</p><p class="headingAnchor" id="H1105159833"><span class="h3">Confirm presence of clinical joint swelling</span><span class="headingEndMark"> — </span>We perform a musculoskeletal examination to confirm the presence of clinical swelling in at least one joint, which is the minimum necessary to be diagnosed with UA.</p><p>Clinical joint swelling caused by synovitis is characterized by soft tissue swelling along the joint margins; it is often warm and tender to palpation, and a joint effusion may be present.</p><p>UA cannot be diagnosed in a patient without clinical joint swelling, which indicates the presence of synovitis. Joint pain, joint tenderness, and imaging abnormalities (in the absence of clinical joint swelling) are <strong>not</strong> sufficient to diagnose UA.</p><p>The musculoskeletal examination in a patient presenting with joint pain is described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain", section on 'Joint examination'</a>.)</p><p class="headingAnchor" id="H3816823015"><span class="h3">Limited role for imaging to confirm synovitis</span><span class="headingEndMark"> — </span>In some patients, joint swelling due to synovitis may be difficult to distinguish from joint swelling due to other causes (eg, fat, edema). In these cases, we use ultrasound of the affected joint to confirm the presence of synovitis. Magnetic resonance imaging (MRI) is a reasonable alternative when ultrasound is not available.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparing modalities</strong> – Both ultrasound and MRI may be helpful for confirming the presence of synovitis [<a href="#rid16">16-18</a>]. However, we prefer to use ultrasound for this purpose, given its low cost and availability compared with MRI. The use of ultrasound and MRI for the evaluation of inflammatory arthritis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6921.html" rel="external">"Imaging techniques for evaluation of the painful joint", section on 'Magnetic resonance imaging'</a> and  <a class="medical medical_review" href="/z/d/html/1832.html" rel="external">"Musculoskeletal ultrasonography: Clinical applications", section on 'Joints'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging alone is inadequate to diagnose UA</strong> – We do not use ultrasound or MRI alone to make a diagnosis of UA in the absence of clinical joint swelling. The specificity of ultrasound or MRI findings for UA in the absence of clinical disease is not clear [<a href="#rid19">19</a>]. Some observations regarding the lack of specificity of ultrasound or MRI for inflammatory arthritis include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ultrasound of healthy, normal joints may demonstrate abnormalities consistent with an inflammatory arthritis, including power Doppler signals [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MRI of healthy, normal joints may demonstrate transient evidence of inflammation and erosions in up to 70 percent of people [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MRI frequently detects erosive disease in patients with systemic lupus erythematosus (SLE) and Sjögren's disease, two diseases not typically associated with joint erosions, raising further questions regarding the specificity of such MRI findings [<a href="#rid23">23,24</a>].</p><p></p><p class="headingAnchor" id="H1544940487"><span class="h2">Exclusion of other disorders</span><span class="headingEndMark"> — </span>After the presence of an inflammatory arthritis has been confirmed, alternate causes of inflammatory arthritis must be excluded. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Most of these other disorders can be readily distinguished from UA by using the following approach:</p><p class="headingAnchor" id="H1766497313"><span class="h3">Identify extraarticular features</span><span class="headingEndMark"> — </span>UA is not associated with extraarticular features, other than constitutional symptoms. Therefore, a thorough history and physical examination should be obtained to determine if there is evidence of extraarticular disease, which may point to an alternative diagnosis  (<a class="graphic graphic_table graphicRef141974" href="/z/d/graphic/141974.html" rel="external">table 1</a>).<strong> </strong>For example, the presence of psoriasis should raise suspicion for a diagnosis of psoriatic arthritis (PsA).</p><p>The approach to evaluating a patient with inflammatory arthritis for extraarticular features is very similar to the approach used when evaluating a patient for rheumatoid arthritis (RA), which is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3387584819"><span class="h3">Plain radiographs for all patients</span><span class="headingEndMark"> — </span>All patients should have plain radiographs of the affected joints and the contralateral joints (for comparison). Patients with arthritis affecting the hands should have plain radiographs of both hands and feet, both to establish the baseline appearance of the joints and to evaluate for changes indicative of other forms of inflammatory arthritis [<a href="#rid25">25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>To evaluate for rheumatoid arthritis</strong> – Plain radiography is particularly useful to identify joint erosions consistent with RA [<a href="#rid25">25,26</a>]. For example, erosions affecting the metacarpophalangeal joints are characteristic of RA but not UA. Patients with early RA may exhibit erosive changes in the feet even in the absence of symptoms.</p><p></p><p class="bulletIndent1">Erosions are found in almost 10 percent of patients with very early RA, but they are less common in patients with UA [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">Studies of radiographic changes in patients with UA have also shown that the presence of two or more erosions conveys a high risk of being diagnosed with RA in the near future [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>To evaluate for other forms of arthritis</strong> – Other forms of inflammatory arthritis (eg, PsA, gout) are also associated with characteristic changes that may be detected on plain radiographs, but these are less likely to appear early in the disease course. However, early osteoarthritis can be diagnosed using plain radiography.</p><p></p><p>The use of plain radiography to diagnose other forms of arthritis is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis", section on 'Plain film radiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis", section on 'Imaging findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/105723.html" rel="external">"Clinical manifestations and diagnosis of osteoarthritis", section on 'Imaging'</a>.)</p><p></p><p class="headingAnchor" id="H1100841793"><span class="h3">Arthrocentesis in patients with large joint involvement</span><span class="headingEndMark"> — </span>We perform arthrocentesis in any patient presenting with an acute arthritis affecting the large joints (eg, knees or shoulders) or the wrist to exclude diagnoses such as infectious arthritis or crystal disease.</p><p>Testing should include a cell count, differential, Gram stain, and culture. The synovial fluid should also be carefully examined for evidence of crystals indicative of a crystalline arthritis (eg, gout, pseudogout). (See  <a class="medical medical_review" href="/z/d/html/1820.html" rel="external">"Monoarthritis in adults: Etiology and evaluation", section on 'Joint aspiration'</a>.)</p><p class="headingAnchor" id="H2487585397"><span class="h3">Review family history</span><span class="headingEndMark"> — </span>We obtain a family history to identify a family history of disease associated with inflammatory arthritis, such as:</p><p class="bulletIndent1"><span class="glyph">●</span>Ankylosing spondylitis</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic rheumatic disease (eg, SLE)</p><p class="bulletIndent1"><span class="glyph">●</span>Psoriasis</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory bowel disease</p><p class="bulletIndent1"><span class="glyph">●</span>RA</p><p></p><p>A family history of any of these disorders should prompt a more detailed history and laboratory evaluation to look for evidence of the same disorder in the patient. However, lack of a family history of any of these disorders does not exclude the diagnosis of UA.</p><p>The evaluation of these diagnoses is discussed in detail in other topic reviews.</p><p class="headingAnchor" id="H4097267922"><span class="h3">Limited role for additional laboratory testing</span><span class="headingEndMark"> — </span>We obtain laboratory tests especially when there is clinical evidence of another disorder  (<a class="graphic graphic_table graphicRef95112" href="/z/d/graphic/95112.html" rel="external">table 2</a>). This approach is very similar to the approach used to evaluate the differential diagnosis of RA, which is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Differential diagnosis'</a>.)</p><p>As an example, patients with a family history of SLE or symptoms related to SLE (eg, photosensitive rash) should undergo additional laboratory testing to exclude SLE as a cause of arthritis. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'</a>.)</p><p>In the absence of clinical features of another rheumatic or inflammatory diagnosis, general screening tests are unhelpful. The evaluation of patients with clinical features of another diagnosis is discussed below. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Laboratory testing required prior to the initiation of pharmacotherapy is discussed below. (See <a class="local">'Pretreatment evaluation'</a> below.)</p><p class="headingAnchor" id="H366390500"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Many diagnoses, including undifferentiated arthritis (UA), are characterized by the presence of synovitis. With some exceptions, UA can be distinguished from alternate diagnoses with a thorough history, physical examination, and selected testing. (See  <a class="medical medical_review" href="/z/d/html/1820.html" rel="external">"Monoarthritis in adults: Etiology and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain"</a> and  <a class="medical medical_review" href="/z/d/html/5614.html" rel="external">"Viral arthritis: Causes and approach to evaluation and management", section on 'Evaluation and diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatoid arthritis</strong> – Rheumatoid arthritis (RA) is the principal diagnosis that should be considered in patients who appear to have UA. In its early stages, RA may not be distinguishable from UA for the following reasons (see  <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with early RA may not have developed the symmetric pattern of joint involvement that is characteristic of this disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with RA may lack rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) (seronegative RA).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with early RA generally lack joint damage or extraarticular manifestations</p><p></p><p class="bulletIndent1">The diagnosis of RA may become clear over time if the patient develops joint damage, extraarticular manifestations, characteristic autoantibodies (RF, ACPA) or a pattern of joint involvement characteristic of RA. (See  <a class="medical medical_review" href="/z/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1">Because the initial treatment approach to UA and RA are similar, differentiating between these two diagnoses when initiating pharmacotherapy may not be crucial for most patients. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of arthritis</strong> – Other disorders that may appear to represent UA include viral arthritis, which is self-limited; psoriatic arthritis (PsA); undifferentiated spondyloarthritis (SpA); or sarcoidosis as well as the wide range of conditions associated with inflammatory arthritis, such as systemic lupus erythematosus (SLE)  (<a class="graphic graphic_table graphicRef95112" href="/z/d/graphic/95112.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">The approach to the differential diagnosis of UA is very similar to the approach used for the differential diagnosis of RA, which is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H366390507"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H91063007"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Our overall approach to the treatment of undifferentiated arthritis (UA) is guided by the following principles:</p><p class="headingAnchor" id="H1306966712"><span class="h3">Early treatment for all patients</span><span class="headingEndMark"> — </span>The goal of early therapy is to suppress of inflammation and the prevention of persistent or recurrent inflammation and irreversible joint damage [<a href="#rid1">1-6,29-33</a>].</p><p>This goal is best accomplished by initiating treatment with a disease-modifying antirheumatic drug (DMARD) as soon as an inflammatory arthritis is detected.</p><p>The immunology underlying early UA may differ substantially from the immunology of chronic UA [<a href="#rid34">34</a>]. Some patients may be more responsive to immunosuppression earlier in their disease course, and patients who are treated early are more likely to experience a complete remission. (See <a class="local">'Rationale for csDMARDs in undifferentiated arthritis'</a> below.)</p><p class="headingAnchor" id="H2402470421"><span class="h3">Specialty referral for all patients</span><span class="headingEndMark"> — </span>We suggest referring all patients with UA to a rheumatologist. Patients with arthritis receive better care when assessed and treated by rheumatologists than generalists, both in terms of an earlier specific diagnosis and better outcomes [<a href="#rid35">35-39</a>].</p><p class="headingAnchor" id="H3574679062"><span class="h3">Multidisciplinary and nonpharmacologic management</span><span class="headingEndMark"> — </span>We use a multidisciplinary management approach that includes patient education, physical and occupational therapy, and pharmacologic therapy, with shared decision-making by the patient and clinician.</p><p>The nonpharmacologic interventions for patients with UA are the same as those used for the treatment of rheumatoid arthritis (RA), including advice regarding smoking cessation. Surgical measures are rarely needed in early stages of arthritis. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7498.html" rel="external">"Nonpharmacologic therapies for patients with rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H156626920"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Prior to initiating pharmacotherapy, we obtain the following tests:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count, blood urea nitrogen, creatinine, and aminotransferases</strong> may help to monitor for adverse reactions to the pharmacotherapy of UA (see <a class="local">'Monitoring and treatment duration'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute phase reactants </strong>(ie, erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]) may be used to help track response to pharmacotherapy by demonstrating declining levels of systemic inflammation (see <a class="local">'Monitoring and treatment duration'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA)</strong> may assist with the selection of pharmacotherapy (see <a class="local">'Initial therapy'</a> below and <a class="local">'Resistant to initial therapy'</a> below)</p><p></p><p>All patients should also have plain radiographs of the affected joints, which can be useful for tracking the presence of joint damage over time. (See <a class="local">'Plain radiographs for all patients'</a> above.)</p><p>Other assessments that should be completed prior to starting or resuming therapy with a conventional synthetic DMARD (csDMARD), or intensifying treatment with use of a biologic DMARD (bDMARD), are discussed in the table  (<a class="graphic graphic_table graphicRef129740" href="/z/d/graphic/129740.html" rel="external">table 3</a>). Our approach to the pretreatment evaluation of patients with UA is similar to the approach used for RA. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Pretreatment evaluation'</a>.)</p><p class="headingAnchor" id="H91064080"><span class="h2">Initial therapy</span></p><p class="headingAnchor" id="H3028122263"><span class="h3">Regimen selection</span><span class="headingEndMark"> — </span>In patients with UA, we suggest treatment with glucocorticoids and a csDMARD.</p><p class="headingAnchor" id="H2030365596"><span class="h4">csDMARD</span><span class="headingEndMark"> — </span>For most patients, we suggest <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX). However, we use <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (SSZ) for patients who may become pregnant and patients with predominantly lower-extremity involvement who lack RF/ACPA. Alternative therapies to MTX and SSZ include <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> (LEF).</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a><strong> for most patients - </strong>For most patients, we suggest MTX.</p><p></p><p class="bulletIndent1">MTX is administered weekly, either orally or subcutaneously. Patients should start at 15 mg weekly, and the dose should be increased over the subsequent month to 20 to 25 mg weekly, using the same approach used for patients with RA.</p><p></p><p class="bulletIndent1">As in RA, MTX therapy should be accompanied by daily folate supplementation (eg, folate 1 mg orally) to prevent side effects.</p><p></p><p class="bulletIndent1">Further details regarding the dosing and administration of MTX are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a>.)</p><p></p><p class="bulletIndent1">We use MTX for most patients because it is widely available, well tolerated, and effective for a broad range of inflammatory arthritides, including RA, which is the most common diagnosis that patients with UA will receive (if they differentiate into another diagnosis). Moreover, MTX has been studied more closely for the treatment of UA than other DMARDs. (See <a class="local">'Rationale for csDMARDs in undifferentiated arthritis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a><strong> for seronegative lower extremity involvement or pregnancy</strong> – We use SSZ for patients who decline MTX or may become pregnant [<a href="#rid40">40</a>]. We also use SSZ for patients with predominantly lower-extremity involvement who lack RF/ACPA. The starting dose is 500 mg twice daily, and the dose should be gradually increased over the subsequent month to a maximum of 1500 mg twice daily.</p><p></p><p class="bulletIndent1">In patients who experience gastrointestinal intolerance, SSZ may be administered three times daily instead of twice daily. This is the same approach used for the treatment of RA and peripheral spondyloarthritis (SpA).</p><p></p><p class="bulletIndent1">The dosing and administration of SSZ is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis", section on 'Dosing and monitoring'</a>.)</p><p></p><p class="bulletIndent1">We use SSZ for patients with lower-extremity involvement because of the increased likelihood that they will evolve into an SpA, for which SSZ (but not MTX) is effective. SSZ is also effective for the treatment of RA and, unlike MTX, is safe for both pregnancy and lactation. We prefer MTX for patients who have RF/ACPA, since they are more likely to evolve to RA, for which MTX is first-line therapy. (See <a class="local">'Rationale for csDMARDs in undifferentiated arthritis'</a> below and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Sulfasalazine'</a>.)</p><p></p><p class="bulletIndent1">We usually do not combine csDMARDs at the start of therapy, since these have not been unequivocally shown to be superior to monotherapy in this population [<a href="#rid41">41,42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative csDMARDs</strong> – We do not use a bDMARD for initial therapy of UA. (See <a class="local">'Avoiding bDMARDs for initial therapy'</a> below.)</p><p></p><p>There are no studies demonstrating which agent (or combinations of agents) is most effective for UA.</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> – HCQ is an alternative for patients with very mild disease activity who are RF- and ACPA-negative but clinically resemble RA more than SpA (eg, patients who have predominantly upper-extremity joint involvement).</p><p></p><p class="bulletIndent2">In patients who are close to achieving remission or low disease activity with MTX, we add HCQ rather than transitioning to a new agent.</p><p></p><p class="bulletIndent2">Dosing and monitoring of HCQ is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease"</a> and  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults", section on 'Hydroxychloroquine'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> – LEF is an alternative for patients with UA, based on experience using this drug for both RA and psoriatic arthritis (PsA).</p><p></p><p class="bulletIndent2">In patients who have had a partial response to MTX, it would be reasonable to add LEF rather than transitioning to a new agent. However, there is an increased risk of transaminitis associated with this approach. Therefore, transitioning to a new agent (eg, a biologic agent) may be associated with fewer complications than using LEF and MTX in combination. (See <a class="local">'Resistant to initial therapy'</a> below.)</p><p></p><p class="bulletIndent2">Dosing and monitoring of LEF is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Leflunomide'</a>.)</p><p></p><p class="headingAnchor" id="H3084717113"><span class="h4">Plus low-dose glucocorticoids</span><span class="headingEndMark"> — </span>We treat with low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for a limited period of time to help achieve disease control (ie, 5 mg daily or less for no more than three months or a single intramuscular injection of glucocorticoids [eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetate 40 to 60 mg]). In studies evaluating initial combination therapy, adding glucocorticoids to DMARDs leads to a long-term reduction in radiographic damage and disease activity [<a href="#rid43">43-46</a>].</p><p>The approach to using glucocorticoids for UA is very similar to the approach used for the treatment of RA, which is discussed extensively elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis", section on 'Efficacy of short-term use'</a>.)</p><p class="headingAnchor" id="H20394522"><span class="h3">Treatment goals</span><span class="headingEndMark"> — </span>The therapeutic goal of treatment in the first three months is clinical improvement; the therapeutic goal of treatment for next three months (and beyond) is to attain remission or low disease activity:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical improvement in the first three months</strong> – The initial therapeutic goal is to achieve significant clinical improvement within three months of treatment, which may be defined as at least a moderate (50 percent) reduction in disease activity using a composite measure such as the Simplified Disease Activity Index (SDAI) or the Clinical Disease Activity Index (CDAI).</p><p></p><p class="bulletIndent1">Both the SDAI and CDAI create a numerical representation of disease activity based on the total number of tender and swollen joints and global assessments of disease activity (by the patient and an objective evaluator). The SDAI also incorporates the CRP. Formulas for both the SDAI and CDAI are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Clinical Disease Activity Index (CDAI)'</a> and  <a class="medical medical_review" href="/z/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Simplified Disease Activity Index (SDAI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remission/low disease activity in the next three months</strong> – The goal of continued therapy is to attain remission or low disease activity within the subsequent three months and to maintain remission or low disease activity thereafter.</p><p></p><p class="bulletIndent1">Remission is defined according to the American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) revised definition of remission for patients with RA [<a href="#rid47">47-50</a>]. (See  <a class="medical medical_review" href="/z/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Criteria for remission'</a>.)</p><p></p><p>This approach to the treatment goals for UA is based on:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical experience in patients with UA [<a href="#rid1">1-3,51-58</a>] (see <a class="local">'Rationale for csDMARDs in undifferentiated arthritis'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence supporting this strategy in patients with RA, consistent with EULAR RA management recommendations [<a href="#rid59">59</a>] (see  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Tight control'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Expert opinion and indirect evidence supporting a similar treat-to-target approach for SpA and PsA (see  <a class="medical medical_review" href="/z/d/html/105691.html" rel="external">"Treatment of peripheral spondyloarthritis", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis", section on 'Monitoring'</a>)</p><p></p><p class="headingAnchor" id="H20249349"><span class="h3">Rationale for csDMARDs in undifferentiated arthritis</span><span class="headingEndMark"> — </span>The decision to start DMARD therapy in patients with UA using a csDMARD such as MTX or SSZ requires balancing of the benefits of early treatment given the risks of untreated disease against the risks of treatment and overtreatment. However, for most patients, the benefits to early treatment outweigh the risks.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of early immunosuppression</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Improved outcomes</strong> – Systematic reviews of drug therapy in UA suggest that early immunosuppression is more effective than placebo at suppressing disease activity and radiographic progression [<a href="#rid1">1,11</a>].</p><p></p><p class="bulletIndent2">An observational study of 335 patients with inflammatory arthritis made the following observations [<a href="#rid60">60</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Overall, patients who were treated with DMARDs had higher level of joint damage than patients who were not treated. This likely reflects that patients who received immunosuppression had greater disease severity at baseline.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>After adjusting for the greater disease severity among patients receiving DMARD therapy, patients who started treatment within six months of symptom onset had less joint damage after five years than patients who received treatment at later timepoints.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mitigating evolution to rheumatoid arthritis</strong> – Early treatment may not prevent UA from evolving to RA. However, early treatment may delay the onset of RA and may reduce the overall functional impairment experienced by such patients [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent2">In one study, 236 patients with preclinical RA (ie, arthralgias and subclinical joint inflammation) were randomized to receive treatment with oral MTX (up to 25 mg/week) and a single intramuscular glucocorticoid injection (120 mg depot <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>) or placebo [<a href="#rid62">62</a>]. After two years of follow-up, equal numbers of patients in both groups developed RA. However, patients treated with MTX had sustained improvements in physical function, pain, morning stiffness and MRI-detected joint inflammation when compared with patients treated with placebo.</p><p></p><p class="bulletIndent2">In RA, the underlying immunologic profile (the pattern of cell types and cytokines found in the synovial membrane) of early disease differs from late disease [<a href="#rid63">63,64</a>]. Also, differences in deoxyribonucleic acid (DNA)-methylation status have been noted in UA patients who progress to RA [<a href="#rid65">65</a>]. A window of opportunity related to these immune characteristics may exist even in UA, given that UA may constitute an early state of RA in a considerable number of patients. During this period, treatment could be more effective than if it were delayed, resulting in a greater possibility of a biologic DMARD-free remission [<a href="#rid66">66-70</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risks of untreated disease</strong> – The risk of inadequately controlled arthritis also includes systemic effects, such as future cardiovascular disease and osteoporosis, which may be fostered and aggravated by the inflammatory state [<a href="#rid30">30,71,72</a>], particularly in patients with positive testing for RF [<a href="#rid73">73,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modest risks of immunosuppression</strong> – The risks of MTX, especially with folate substitution, or SSZ are generally modest, and their adverse effects are well recognized, with many decades of experience in the use of these agents and in the monitoring, prevention, and management of their risks. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis", section on 'Desensitization'</a>.)</p><p></p><p class="bulletIndent1">Most side effects are managed easily when patients are well informed and monitored regularly. (See <a class="local">'Monitoring and treatment duration'</a> below.)</p><p></p><p class="bulletIndent1">It is rare to see new adverse events occurring after three months of therapy, unless doses are changed or other comorbidities develop [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H338510655"><span class="h3">Avoiding bDMARDs for initial therapy</span><span class="headingEndMark"> — </span>We generally avoid starting with bDMARDs because we would risk overtreatment of a large proportion of patients. Moreover, use of these agents is generally not required because of the typically mild disease seen in these patients.</p><p>Most trials in early RA comparing csDMARDs and glucocorticoids (even at low doses) versus the combination of a csDMARD and a bDMARD have not revealed any major differences in outcomes [<a href="#rid76">76-79</a>]. An additional concern with the use of tumor necrosis factor (TNF) inhibitors is their somewhat higher risk of infections and other adverse effects. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H91063762"><span class="h2">Resistant to initial therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of treatment resistance</strong> – We define treatment resistance using one of the two following criteria (see <a class="local">'Treatment goals'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Failure to achieve a 50 percent reduction in disease activity after three months of DMARD therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Failure to achieve low disease activity or remission after six months of DMARD therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting the treatment approach</strong> – In patients with UA resistant to initial therapies, the approach depends on the regimen used for initial therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a><strong> resistant</strong> – In patients who have had an inadequate response to MTX, we add or transition to monotherapy with a biologic agent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resistant to csDMARD other than </strong><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> – In patients who have an inadequate response to a csDMARD other than MTX (eg, SSZ, LEF, HCQ), we switch to MTX. It would be reasonable to switch to monotherapy with a biologic agent if the patient has contraindications for MTX.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive antiinflammatory</strong> – We also treat most patients with nonsteroidal antiinflammatory drugs (NSAIDs) and/or short-term (&lt;3 months) glucocorticoids to help control disease activity temporarily until the DMARDs are effective. (See <a class="local">'Adjunctive role of antiinflammatory agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting a biologic agent</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tumor necrosis factor inhibitors for most methotrexate-resistant patients</strong> — In patients with UA who require treatment with a biologic agent, we generally select a TNF inhibitor. Starting doses are the same as those used in RA. We suggest the use of TNF inhibitors because of their low cost, wide availability, and therapeutic efficacy for multiple forms of inflammatory arthritis (eg, RA, PsA, ankylosing spondylitis). These data are discussed elsewhere in the appropriate topic reviews.</p><p></p><p class="bulletIndent2">If treatment goals (ie, clinical improvement within three months and remission or low disease activity at six months) are not met with a TNF inhibitor, we transition to a different bDMARD, depending on disease characteristics.</p><p></p><p class="bulletIndent2">One small trial lends some support to the hypothesis that treatment of UA with a TNF inhibitor may lead to cure for some patients [<a href="#rid80">80</a>]. In a study of 90 patients with UA, initial treatment with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and MTX was associated with greater rates of drug-free remission than treatment with MTX alone (75 versus 20 percent). Despite this observation, we believe the bulk of the evidence continues to support using a csDMARD for the initial therapy of UA. (See <a class="local">'Avoiding bDMARDs for initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biologic selection for tumor necrosis factor inhibitor-resistant patients</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Interleukin 6 receptor or Janus kinase inhibitor</strong> – For patients who are expected to evolve towards RA (eg, RF-/ACPA-positive, predominantly upper-extremity joint disease, presence of tenosynovitis [<a href="#rid81">81-85</a>]), we would use an interleukin 6 (IL-6) or Janus kinase (JAK) inhibitor, based on their efficacy for RA. In RA studies, monotherapy with either an IL-6 or JAK inhibitor is more efficacious than TNF inhibitor monotherapy [<a href="#rid86">86,87</a>]. However, JAK inhibitors may be associated with an increased risk of cardiovascular events and malignancy and respective risk factors should be thoroughly evaluated.</p><p></p><p class="bulletIndent3">Both IL-6 receptor and JAK inhibitors are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'IL-6 inhibition'</a> and  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'JAK inhibitors'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Interleukin 17 or interleukin 23 inhibitor</strong> – For patients who are expected to evolve towards a spondyloarthropathy (eg, RF-/ACPA-negative, predominantly lower extremity joint disease), we would use an IL-17 inhibitor based on its efficacy for ankylosing spondylitis and PsA.</p><p></p><p class="bulletIndent3">Patients who are expected to evolve towards PsA (eg, patients with psoriasis) could also be treated with an IL-12/23 inhibitor (eg, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>) or IL-23 inhibitor (eg, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>).</p><p></p><p class="bulletIndent3">These agents are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Interleukin 17 inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis", section on 'Patients without concomitant axial disease'</a>.)</p><p></p><p class="headingAnchor" id="H156627050"><span class="h2">Adjunctive role of antiinflammatory agents</span><span class="headingEndMark"> — </span>We use antiinflammatory therapies, including systemic and intraarticular glucocorticoids and NSAIDs, primarily for temporary control of disease activity in patients who are starting/changing DMARDs and/or patients experiencing a disease flare.</p><p>However, the long-term use of both glucocorticoids and NSAIDs is associated with substantial side effects. Moreover, although NSAIDs act rapidly to reduce inflammation in UA or RA, they do not prevent joint damage. More detailed discussions of NSAIDs and glucocorticoids for the treatment of RA are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Symptomatic treatment with antiinflammatory drugs'</a>.)</p><p class="headingAnchor" id="H20249940"><span class="h2">Drug therapy for flares</span><span class="headingEndMark"> — </span>Patients with UA, like those with RA, may experience disease flares. Our approach to the management of disease flares is the same as our approach in RA, which is described separately. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Drug therapy for flares'</a>.)</p><p class="headingAnchor" id="H3466741"><span class="h1">MONITORING AND TREATMENT DURATION</span><span class="headingEndMark"> — </span>We monitor disease activity and drug toxicity using the same approach as for patients with rheumatoid arthritis (RA), which is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Assessment and monitoring'</a>.)</p><p>Our approach to the long-term therapy of undifferentiated arthritis (UA) is similar to the approach used for patients with RA. Notably, patients who have had UA for over one year are unlikely to remit spontaneously or evolve to another diagnosis, as discussed below. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H366390533"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients initially diagnosed with undifferentiated arthritis (UA) generally have one of three long-term outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent undifferentiated arthritis</strong> – Approximately 21 to 87 percent of the patients initially diagnosed with UA will not differentiate into another diagnosis, even after one or two years of follow-up [<a href="#rid7">7,8,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation to another diagnosis</strong> – Approximately 13 to 55 percent of patients initially diagnosed with UA will be rediagnosed with RA after one year of follow-up [<a href="#rid8">8,10</a>]. Another 6 to 20 percent of patients will be diagnosed with another form of inflammatory arthritis (eg, psoriatic arthritis [PsA]), and up to 16 percent will be diagnosed with osteoarthritis.</p><p></p><p class="bulletIndent1">Patients with UA who present with a monoarthritis are the least likely to progress to RA. One study examined the one-year outcomes of 310 patients with UA who lacked rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) [<a href="#rid14">14</a>]. After one year of follow-up, progression to RA was experienced by 2 percent of patients who presented with a monoarthritis, 10 percent of patients who presented with an oligoarthritis, and 21 percent of patients who presented with a polyarthritis.</p><p></p><p class="bulletIndent1">If patients evolve from UA to a specific diagnosis, this will typically occur within a year of presentation. In such cases, the patient’s treatment regimen may need to be altered to reflect the patient’s new diagnosis (eg, RA, PsA). (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Pharmacologic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resolution of the inflammatory arthritis</strong> – Some patients initially diagnosed with UA will experience complete resolution of their inflammatory arthritis, without pharmacotherapy, generally in the first few months following diagnosis.</p><p></p><p class="bulletIndent1">The specific percent of patients with UA who experience spontaneous resolution of their disease is unknown. However, approximately 10 to 40 percent of patients with any type of early arthritis (many of whom have UA) will experience spontaneous resolution of their inflammatory arthritis within one year [<a href="#rid10">10</a>]. The use of glucocorticoids does not increase the rate of spontaneous resolution of UA [<a href="#rid88">88,89</a>].</p><p></p><p class="bulletIndent1">Patients with UA who present with a monoarthritis are the most likely to experience spontaneous disease resolution. One study examined the one-year outcomes of 310 patients with UA who lacked RF or ACPA [<a href="#rid14">14</a>]. After one year of follow up, spontaneous resolution occurred in 72 percent of patients with UA who presented with a monoarthritis, 40 percent of patients who presented with an oligoarthritis, and 34 percent of patients who presented with a polyarthritis.</p><p></p><p class="bulletIndent1">Patients with UA for longer than two to three months are unlikely to enter a spontaneous remission. In one study of very early inflammatory arthritis, patients who had more than eight weeks of symptoms were unlikely to experience spontaneous remission [<a href="#rid88">88</a>].</p><p></p><p class="headingAnchor" id="H3609977789"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120030.html" rel="external">"Society guideline links: Undifferentiated early inflammatory arthritis"</a>.)</p><p class="headingAnchor" id="H366390521"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Undifferentiated arthritis (UA) is a diagnosis of exclusion. UA refers to patients who have at least one clinically swollen joint but do not meet criteria for an alternative diagnosis. Arthralgias in the absence of a clinically swollen joint are not sufficient to make a diagnosis of UA. (See <a class="local">'Clinical and laboratory features'</a> above and <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients determined to have UA typically have the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms for several weeks to months</p><p class="bulletIndent2"><span class="glyph">•</span>Morning stiffness</p><p class="bulletIndent2"><span class="glyph">•</span>Less than four swollen joints</p><p class="bulletIndent2"><span class="glyph">•</span>Arthritis affecting the upper extremities more often than the lower extremities</p><p class="bulletIndent2"><span class="glyph">•</span>Normal or modestly elevated levels of acute phase reactants</p><p></p><p class="bulletIndent1">Rheumatoid factor (RF) and/or anti-citrullinated peptide antibodies (ACPA) are each positive in approximately 10 percent of patients with UA. (See <a class="local">'Clinical and laboratory features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and differential diagnosis</strong> – The diagnostic evaluation includes a medical history, physical examination, and laboratory and imaging studies to confirm the presence of an inflammatory arthritis (ie, synovitis associated with joint swelling) and to exclude other disorders. Such exclusionary findings may include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extraarticular features that suggest another diagnosis</p><p class="bulletIndent2"><span class="glyph">•</span>Arthrocentesis consistent with an infectious or crystal arthritis</p><p class="bulletIndent2"><span class="glyph">•</span>Imaging studies characteristic of specific arthritic disorders</p><p></p><p class="bulletIndent1">Some features suggestive of an alternate diagnosis are found in the table  (<a class="graphic graphic_table graphicRef95112" href="/z/d/graphic/95112.html" rel="external">table 2</a>). (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial pharmacotherapy</strong> – We use the following approach for the initial treatment of patients presenting with UA (see <a class="local">'Initial therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a><strong> for most patients</strong> – For most patients, we suggest methotrexate (MTX) rather than other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We use MTX for most patients because it is widely available, well tolerated, and effective for a broad range of inflammatory arthritides, including rheumatoid arthritis (RA) and UA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a><strong> for selected patients</strong> – Sulfasalazine (SSZ) is appropriate for patients who have predominantly lower-joint disease and lack RF/ACPA (who are more likely to evolve into a spondyloarthropathy) or may become pregnant (since SSZ is safe for both pregnancy and lactation).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-dose </strong><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a><strong> for immediate disease control</strong> – We also suggest adjunctive therapy with prednisone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use only a short course of prednisone for a limited period of time (eg, less than 10 mg daily for less than six months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – The initial therapeutic goal is to achieve significant clinical improvement within three months, which may be defined as at least a moderate (50 percent) reduction in disease activity using a composite measure. (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of resistant disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who fail to respond to a csDMARD other than MTX, we suggest transitioning to MTX (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who fail to respond to MTX (or who have failed to respond to other csDMARDs and have contraindications to MTX), we suggest adding or transitioning to a tumor necrosis factor (TNF) inhibitor rather than other csDMARDs or other bDMARDs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">We suggest TNF inhibitors over other agents because of their broad availability and efficacy for a large range of inflammatory arthridities, including RA and spondyloarthritis (SpA). (See <a class="local">'Resistant to initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiinflammatory therapies for temporary disease control</strong> – We use antiinflammatory therapies, including glucocorticoids and nonsteroidal antiinflammatory drugs (NSAIDs), for temporary control of disease activity in patients starting/changing DMARD therapy and in patients experiencing a disease flare. (See <a class="local">'Adjunctive role of antiinflammatory agents'</a> above and <a class="local">'Drug therapy for flares'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment and monitoring strategies</strong> – The approaches to preventive and nonpharmacologic therapy, pretreatment evaluation, and monitoring of disease activity and for drug toxicity follow the same strategies as for patients with RA. (See <a class="local">'Treatment'</a> above and <a class="local">'Pretreatment evaluation'</a> above and <a class="local">'Monitoring and treatment duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The definition of UA varies across studies. However, approximately 10 to 40 percent of patients with UA will remit spontaneously within one year, while 13 to 55 percent will eventually be rediagnosed with RA. Approximately 21 to 87 percent of patients initially diagnosed with UA will not differentiate into another diagnosis, even after one to two years of follow-up. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wevers-de Boer KV, Heimans L, Huizinga TW, Allaart CF. Drug therapy in undifferentiated arthritis: a systematic literature review. Ann Rheum Dis 2013; 72:1436.</a></li><li><a class="nounderline abstract_t">van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424.</a></li><li><a class="nounderline abstract_t">Lukas C, Combe B, Ravaud P, et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011; 63:1804.</a></li><li><a class="nounderline abstract_t">van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31:519.</a></li><li><a class="nounderline abstract_t">van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21:425.</a></li><li><a class="nounderline abstract_t">Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42:1854.</a></li><li><a class="nounderline abstract_t">Tamai M, Grundeken V, Arima K, et al. Predictive Value of Magnetic Resonance Imaging-detected Tenosynovitis of the Metacarpophalangeal and Wrist Joints for the Development of Rheumatoid Arthritis among Patients with Undifferentiated Arthritis. Intern Med 2023; 62:2329.</a></li><li><a class="nounderline abstract_t">Norli ES, Brinkmann GH, Kvien TK, et al. Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis. RMD Open 2017; 3:e000573.</a></li><li><a class="nounderline abstract_t">Sidhu N, Wouters F, Niemantsverdriet E, van der Helm-van Mil AHM. MRI-detected synovitis of the small joints predicts rheumatoid arthritis development in large joint undifferentiated inflammatory arthritis. Rheumatology (Oxford) 2022; 61:SI23.</a></li><li><a class="nounderline abstract_t">Hazes JM, Luime JJ. The epidemiology of early inflammatory arthritis. Nat Rev Rheumatol 2011; 7:381.</a></li><li><a class="nounderline abstract_t">Verstappen M, Matthijssen XME, van der Helm-van Mil AHM. Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort. Rheumatology (Oxford) 2022; 61:3212.</a></li><li><a class="nounderline abstract_t">van Nies JA, Brouwer E, van Gaalen FA, et al. Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics. Ann Rheum Dis 2013; 72:1295.</a></li><li><a class="nounderline abstract_t">Krabben A, Huizinga TW, van der Helm-van Mil AH. Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis. Ann Rheum Dis 2012; 71:238.</a></li><li><a class="nounderline abstract_t">den Hollander NK, Verstappen M, van Dijk BT, et al. Disentangling heterogeneity in contemporary undifferentiated arthritis - A large cohort study using latent class analysis. Semin Arthritis Rheum 2023; 63:152251.</a></li><li><a class="nounderline abstract_t">Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.</a></li><li><a class="nounderline abstract_t">Østergaard M, Ejbjerg B, Szkudlarek M. Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography. Best Pract Res Clin Rheumatol 2005; 19:91.</a></li><li><a class="nounderline abstract_t">Freeston JE, Wakefield RJ, Conaghan PG, et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis 2010; 69:417.</a></li><li><a class="nounderline abstract_t">van de Stadt LA, Bos WH, Meursinge Reynders M, et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther 2010; 12:R98.</a></li><li><a class="nounderline abstract_t">Machado P, Castrejon I, Katchamart W, et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2011; 70:15.</a></li><li><a class="nounderline abstract_t">Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Doppler ultrasound findings in healthy wrists and finger joints. Ann Rheum Dis 2004; 63:644.</a></li><li><a class="nounderline abstract_t">Mangnus L, van Steenbergen HW, Reijnierse M, van der Helm-van Mil AH. Magnetic Resonance Imaging-Detected Features of Inflammation and Erosions in Symptom-Free Persons From the General Population. Arthritis Rheumatol 2016; 68:2593.</a></li><li><a class="nounderline abstract_t">Mangnus L, Schoones JW, van der Helm-van Mil AH. What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data. RMD Open 2015; 1:e000005.</a></li><li><a class="nounderline abstract_t">Boutry N, Hachulla E, Flipo RM, et al. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome. Radiology 2005; 236:593.</a></li><li><a class="nounderline abstract_t">Boeters DM, Nieuwenhuis WP, van Steenbergen HW, et al. Are MRI-detected erosions specific for RA? A large explorative cross-sectional study. Ann Rheum Dis 2018; 77:861.</a></li><li><a class="nounderline abstract_t">van der Heijde D, van der Helm-van Mil AH, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013; 72:479.</a></li><li><a class="nounderline abstract_t">Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580.</a></li><li><a class="nounderline abstract_t">Machold KP, Stamm TA, Eberl GJ, et al. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29:2278.</a></li><li><a class="nounderline abstract_t">Thabet MM, Huizinga TW, van der Heijde DM, van der Helm-van Mil AH. The prognostic value of baseline erosions in undifferentiated arthritis. Arthritis Res Ther 2009; 11:R155.</a></li><li><a class="nounderline abstract_t">Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54:2784.</a></li><li><a class="nounderline abstract_t">Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11:234.</a></li><li><a class="nounderline abstract_t">Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:122.</a></li><li><a class="nounderline abstract_t">Fries JF, Bloch DA, Sharp JT, et al. Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 1986; 29:1.</a></li><li><a class="nounderline abstract_t">Smolen JS, Aletaha D, Steiner G. Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis 2009; 68:159.</a></li><li><a class="nounderline abstract_t">Raza K. The Michael Mason prize: early rheumatoid arthritis--the window narrows. Rheumatology (Oxford) 2010; 49:406.</a></li><li><a class="nounderline abstract_t">Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards. Ann Intern Med 1997; 127:52.</a></li><li><a class="nounderline abstract_t">Panush RS, Carias K, Kramer N, Rosenstein ED. Acute arthritis in the hospital: comparison of rheumatologic with nonrheumatologic care. J Clin Rheumatol 1995; 1:74.</a></li><li><a class="nounderline abstract_t">Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care. Arch Intern Med 1993; 153:2229.</a></li><li><a class="nounderline abstract_t">Memel DS, Somerset M. General practitioner and specialist care: The perceptions of people with rheumatoid arthritis. Prim Health Care Res Dev 2003; 4:29.</a></li><li><a class="nounderline abstract_t">Schmajuk G, Trivedi AN, Solomon DH, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011; 305:480.</a></li><li><a class="nounderline abstract_t">Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75:795.</a></li><li><a class="nounderline abstract_t">Gaujoux-Viala C, Smolen JS, Landewé R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:1004.</a></li><li><a class="nounderline abstract_t">Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010; :CD008495.</a></li><li><a class="nounderline abstract_t">Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:1010.</a></li><li><a class="nounderline abstract_t">Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52:3360.</a></li><li><a class="nounderline abstract_t">Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:3371.</a></li><li><a class="nounderline abstract_t">Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329.</a></li><li><a class="nounderline abstract_t">Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404.</a></li><li><a class="nounderline abstract_t">Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63:573.</a></li><li><a class="nounderline abstract_t">Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis 2023; 82:74.</a></li><li><a class="nounderline abstract_t">Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol 2023; 75:15.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.</a></li><li><a class="nounderline abstract_t">van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34.</a></li><li><a class="nounderline abstract_t">Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012; 71:1190.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492.</a></li><li><a class="nounderline abstract_t">Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631.</a></li><li><a class="nounderline abstract_t">Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73:6.</a></li><li><a class="nounderline abstract_t">Coates LC, Moverley AR, McParland L, et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: Tight control improves outcome. Arthritis Rheum 2013; 65:S346.</a></li><li><a class="nounderline abstract_t">Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76:948.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023; 82:3.</a></li><li><a class="nounderline abstract_t">Bukhari MA, Wiles NJ, Lunt M, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48:46.</a></li><li><a class="nounderline abstract_t">Gerlag DM, Safy M, Maijer KI, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis 2019; 78:179.</a></li><li><a class="nounderline abstract_t">Krijbolder DI, Verstappen M, van Dijk BT, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 2022; 400:283.</a></li><li><a class="nounderline abstract_t">Raza K, Falciani F, Curnow SJ, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7:R784.</a></li><li><a class="nounderline abstract_t">Tak PP. Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment? J Rheumatol Suppl 2005; 72:25.</a></li><li><a class="nounderline abstract_t">de la Calle-Fabregat C, Niemantsverdriet E, Cañete JD, et al. Prediction of the Progression of Undifferentiated Arthritis to Rheumatoid Arthritis Using DNA Methylation Profiling. Arthritis Rheumatol 2021; 73:2229.</a></li><li><a class="nounderline abstract_t">Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69:1636.</a></li><li><a class="nounderline abstract_t">van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011; 70:1389.</a></li><li><a class="nounderline abstract_t">Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70:315.</a></li><li><a class="nounderline abstract_t">van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology (Oxford) 2012; 51:1120.</a></li><li><a class="nounderline abstract_t">van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014; 73:861.</a></li><li><a class="nounderline abstract_t">Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70:8.</a></li><li><a class="nounderline abstract_t">Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21:885.</a></li><li><a class="nounderline abstract_t">Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46:2010.</a></li><li><a class="nounderline abstract_t">Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008; 35:1009.</a></li><li><a class="nounderline abstract_t">Aletaha D, Smolen JS. Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis. Arthritis Rheum 2002; 47:181.</a></li><li><a class="nounderline abstract_t">Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 2014; 73:1356.</a></li><li><a class="nounderline abstract_t">Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014; 73:75.</a></li><li><a class="nounderline abstract_t">Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406.</a></li><li><a class="nounderline abstract_t">Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020; 371:m4328.</a></li><li><a class="nounderline abstract_t">Stamm TA, Machold KP, Aletaha D, et al. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Res Ther 2018; 20:174.</a></li><li><a class="nounderline abstract_t">Verheul MK, Böhringer S, van Delft MAM, et al. Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals. Arthritis Rheumatol 2018; 70:1721.</a></li><li><a class="nounderline abstract_t">Studenic P, Alunno A, Sieghart D, et al. Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. Ther Adv Musculoskelet Dis 2021; 13:1759720X211022533.</a></li><li><a class="nounderline abstract_t">Nieuwenhuis WP, Krabben A, Stomp W, et al. Evaluation of magnetic resonance imaging-detected tenosynovitis in the hand and wrist in early arthritis. Arthritis Rheumatol 2015; 67:869.</a></li><li><a class="nounderline abstract_t">McQueen FM. The MRI view of synovitis and tenosynovitis in inflammatory arthritis: implications for diagnosis and management. Ann N Y Acad Sci 2009; 1154:21.</a></li><li><a class="nounderline abstract_t">Matthijssen XME, Wouters F, Sidhu N, et al. Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study. Ann Rheum Dis 2021; 80:974.</a></li><li><a class="nounderline abstract_t">Kremer JM, Rigby W, Singer NG, et al. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial. Arthritis Rheumatol 2018; 70:1200.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495.</a></li><li><a class="nounderline abstract_t">Machold KP, Landewé R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 2010; 69:495.</a></li><li><a class="nounderline abstract_t">Verstappen SM, McCoy MJ, Roberts C, et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 2010; 69:503.</a></li></ol></div><div id="topicVersionRevision">Topic 17052 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744979" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug therapy in undifferentiated arthritis: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469099" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21452295" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from theÉtude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386548" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7516430" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10513799" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36631087" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictive Value of Magnetic Resonance Imaging-detected Tenosynovitis of the Metacarpophalangeal and Wrist Joints for the Development of Rheumatoid Arthritis among Patients with Undifferentiated Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29299343" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34164662" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : MRI-detected synovitis of the small joints predicts rheumatoid arthritis development in large joint undifferentiated inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The epidemiology of early inflammatory arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850952" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22952388" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21953339" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Undifferentiated arthritis characteristics and outcomes when applying the 2010 and 1987 criteria for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37607441" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disentangling heterogeneity in contemporary undifferentiated arthritis - A large cohort study using latent class analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20872595" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15588973" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19359260" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20487531" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20724311" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140770" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Doppler ultrasound findings in healthy wrists and finger joints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27213695" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Magnetic Resonance Imaging-Detected Features of Inflammation and Erosions in Symptom-Free Persons From the General Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26509042" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972342" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29490980" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Are MRI-detected erosions specific for RA? A large explorative cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378540" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699241" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12415582" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19832979" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The prognostic value of baseline erosions in undifferentiated arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16947781" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378270" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inflammatory bone loss: pathogenesis and therapeutic intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10725061" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The links between joint damage and disability in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3947405" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139203" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Does damage cause inflammation? Revisiting the link between joint damage and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955223" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Michael Mason prize: early rheumatoid arthritis--the window narrows.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214253" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077950" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute arthritis in the hospital: comparison of rheumatologic with nonrheumatologic care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215726" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : General practitioner and specialist care: The perceptions of people with rheumatoid arthritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285425" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888948" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447954" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393970" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448288" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16255010" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16255011" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393128" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292833" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21294106" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36280238" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36274193" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444750" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546736" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22454398" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161836" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215140" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treating rheumatoid arthritis to target: recommendations of an international task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23749611" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: Tight control improves outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27979873" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : 2016 update of the EULAR recommendations for the management of early arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36357155" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528102" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504445" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35871815" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987480" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660460" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34105306" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prediction of the Progression of Undifferentiated Arthritis to Rheumatoid Arthritis Using DNA Methylation Profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421345" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515916" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068104" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22337939" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23572339" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109513" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17870034" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comorbidities in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209502" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412312" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Mortality trends in rheumatoid arthritis: the role of rheumatoid factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11954012" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716067" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23912798" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371885" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33268527" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092827" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781231" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34539818" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510520" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of magnetic resonance imaging-detected tenosynovitis in the hand and wrist in early arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250228" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The MRI view of synovitis and tenosynovitis in inflammatory arthritis: implications for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33547063" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29575803" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873530" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223838" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19825849" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
